Summary
Basal cell carcinoma is the most frequent cutaneous neoplasm, with slowly progressive nature and locally invasive behavior. Despite the low metastatic potential, local tissue destruction and disfigurement caused by the tumor can be large if not eradicated in time by early diagnosis and treatment. Both genetic predisposition and exposure to environmental risks are involved in the pathogenesis of the malignant transformation in BCC. The total number of nonmelanocytic skin cancers is a risk factor for recurrence of previous tumor, on the one hand, as well as for the formation of new ones, on the other. It is still unclear what environmental and genetic factors contribute to the development of multiple nonsyndromic BCCs. We present a man with multiple sporadic, nonsyndromic BCCs, with a history of even more lesions, removed earlier, as we discuss the potential triggering risk factors and pathogenic mechanisms of malignant transformation and the further appropriate therapeutic options. The early detection and eradication of these tumors are of importance for treatment effectiveness and quality of life because although rarely metastatic, BCCs could have an aggressive course and behavior which can lead to severe disfiguration and destruction.
Similar content being viewed by others
References
Hallaji Z, Rahimi H, Mirshams-Shahshahani M. Comparison of risk factors of single basal cell carcinoma with multiple basal cell carcinomas. Indian J Dermatol. 2011;56(4):398–402.
Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 2007;11(1):19–30.
Madan V, Hoban P, Strange RC, Fryer AA, Lear JT. Genetics and risk factors for basal cell carcinoma. Br J Dermatol. 2006;154(Suppl 1):5–7.
Marghoob A, Kopf AW, Bart RS, Sanfilippo L, Silverman MK, Lee P, Levy E, Vossaert KA, Yadav S, Abadir M. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol. 1993;28(1):22–8.
Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer. Arch Dermatol. 2000;136:1524–30.
Chen J, Ruczinski I, Jorgensen TJ, Yenokyan G, Yao Y, Alani R, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst. 2008;100:1215–22.
Troyanova P, Danon S, Ivanova T. Nonmelanoma skin cancers and risk of subsequent malignancies: a cancer registry-based study in Bulgaria. Neoplasma. 2002;49:81–5.
Levi F, Randimbison L, Maspoli M, Te VC, La Vecchia C. High incidence of second basal cell skin cancers. Int J Cancer. 2006;119:1505–7.
Ramachandran S, Fryer AA, Lovatt TJ, Smith AG, Lear JT, Jones PW, Strange RC. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. Cancer Lett. 2003;189(2):175–81.
Wallberg P, Kaaman T, Lindberg M. Multiple basal cell carcinoma. A clinical evaluation of risk factors. Acta Derm Venereol. 1998;78:127–9.
Sekulic A, Von Hoff D. Hedgehog pathway inhibition. Cell. 2016;164(5):831.
Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. Br J Dermatol. 2011;165(3):612–25.
Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816–24.
Ramelyte E, Amann VC, Dummer R. Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opin Pharmacother. 2016;17(14):1963–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
G. Tchernev, I. Pidakev, I. Lozev, T. Lotti, and U. Wollina declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Tchernev, G., Pidakev, I., Lozev, I. et al. Multiple nonsyndromic acquired basal cell carcinomas. Wien Med Wochenschr 167, 134–138 (2017). https://doi.org/10.1007/s10354-017-0545-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10354-017-0545-7